These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3239704)

  • 1. Synergistic antiproliferative effects on HL-60 cells: deferoxamine enhances cytosine arabinoside, methotrexate, and daunorubicin cytotoxicity.
    Estrov Z; Cohen A; Gelfand EW; Freedman MH
    Am J Pediatr Hematol Oncol; 1988; 10(4):288-91. PubMed ID: 3239704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of daunorubicin and cytarabine on cell line NB4].
    Luo ZG; Zhong L; Chen FY; Wang HR; Ouyang RR
    Zhonghua Xue Ye Xue Za Zhi; 2007 Apr; 28(4):247-9. PubMed ID: 17877202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro.
    Akutsu M; Furukawa Y; Tsunoda S; Izumi T; Ohmine K; Kano Y
    Leukemia; 2002 Sep; 16(9):1808-17. PubMed ID: 12200697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
    Niitsu N; Higashihara M; Honma Y
    Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination of quercetin and cytosine arabinoside synergistically inhibits leukemic cell growth.
    Teofili L; Pierelli L; Iovino MS; Leone G; Scambia G; De Vincenzo R; Benedetti-Panici P; Menichella G; Macrì E; Piantelli M
    Leuk Res; 1992; 16(5):497-503. PubMed ID: 1625476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
    Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo effects of deferoxamine in neonatal acute leukemia.
    Estrov Z; Tawa A; Wang XH; Dubé ID; Sulh H; Cohen A; Gelfand EW; Freedman MH
    Blood; 1987 Mar; 69(3):757-61. PubMed ID: 3493042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antileukemic effects of deferoxamine on human myeloid leukemia cell lines.
    Becton DL; Roberts B
    Cancer Res; 1989 Sep; 49(17):4809-12. PubMed ID: 2758414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neplanocin A, a potent inhibitor of S-adenosylhomocysteine hydrolase, potentiates granulocytic differentiation of acute promyelocytic leukemia cells induced by all-trans retinoic acid.
    Niitsu N; Yamamoto-Yamaguchi Y; Kanatani Y; Shuto S; Matsuda A; Umeda M; Honma Y
    Exp Hematol; 1997 Nov; 25(12):1296-303. PubMed ID: 9357974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential combination of methotrexate and 1-beta-D-arabinofuranosylcytosine shows synergistic effect on the generation of DNA strand breaks in a human promyelocytic leukemia cell line.
    Tanizawa A; Kubota M; Takimoto T; Kito T; Akiyama Y; Kiriyama Y; Mikawa H
    Adv Exp Med Biol; 1989; 253B():349-54. PubMed ID: 2610122
    [No Abstract]   [Full Text] [Related]  

  • 11. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of differentiation of acute promyelocytic leukemia cells by a cytidine deaminase-resistant analogue of 1-beta-D-arabinofuranosylcytosine, 1-(2-deoxy-2-methylene-beta-D-erythro-pentofuranosyl)cytidine.
    Niitsu N; Ishii Y; Matsuda A; Honma Y
    Cancer Res; 2001 Jan; 61(1):178-85. PubMed ID: 11196157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of in vitro chemosensitivity in acute myelogenous leukemia cell line by GM-CSF: opposing effects observed with different cytotoxic drugs and time exposure.
    Ciaiolo C; Ferrero D; Pugliese A; Ortolano B; Borrione P; Pileri A
    Leuk Res; 1999 Oct; 23(10):931-8. PubMed ID: 10573139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.
    Masquelier M; Vitols S
    Biochem Pharmacol; 2004 May; 67(9):1639-46. PubMed ID: 15081863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of G-CSF, GM-CSF and IL-3 on cytosine arabinoside- and daunorubicin-mediated cytotoxicity of acute myeloid leukemia cells and normal myeloid progenitors.
    Waga K; Furusawa S; Nagashima S; Saito K; Shishido H
    Int J Hematol; 1992 Aug; 56(1):17-27. PubMed ID: 1391803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-alpha enhances the cytotoxic and cytostatic activities of chemotherapeutic drugs in human myeloid leukemia cells.
    Hassan HT; Grell S; Borrmann-Danso U; Freund M
    J Interferon Cytokine Res; 1996 Feb; 16(2):139-46. PubMed ID: 8742366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S; Turner AJ; Bartimole TM; Nelms PA; Joe VC; Jarvis WD
    Oncol Res; 1994; 6(2):87-99. PubMed ID: 7949469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
    Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
    Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
    Tanaka M; Kano Y; Akutsu M; Tsunoda S; Izumi T; Yazawa Y; Miyawaki S; Mano H; Furukawa Y
    Anticancer Res; 2009 Nov; 29(11):4589-96. PubMed ID: 20032408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
    Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
    Cancer Res; 2001 Jan; 61(1):172-7. PubMed ID: 11196156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.